Summary
Abbott Laboratories (ABT) has filed an 8-K report detailing its financial results for the second quarter of 2025, announced on July 17, 2025. The report primarily incorporates a press release that provides a non-GAAP view of the company's earnings. Investors should note that Abbott utilizes non-GAAP financial measures, which exclude items such as acquisition-related expenses, restructuring costs, fair value adjustments to contingent consideration, certain regulatory costs, prior tax benefit adjustments, and intangible amortization. The company states these measures offer greater visibility into ongoing business performance and are used internally for assessment. While the 8-K does not provide specific Q2 2025 financial figures within the report itself, it directs investors to an accompanying press release (Exhibit 99.1) for detailed results and analysis. Investors are advised to consider these non-GAAP figures alongside the company's GAAP financial measures, as the non-GAAP metrics are presented for informational purposes to aid in evaluating operational performance and should not be viewed as a substitute for GAAP-based reporting.
Key Highlights
- 1Abbott Laboratories released its Q2 2025 financial results on July 17, 2025, via an 8-K filing.
- 2The report references an accompanying press release (Exhibit 99.1) containing the detailed financial results.
- 3Abbott employs non-GAAP financial measures, excluding specific items like acquisition costs, restructuring, and intangible amortization, to present operational performance.
- 4These non-GAAP measures are intended to provide investors with better insight into the ongoing business performance.
- 5The company emphasizes that non-GAAP measures should be considered in addition to, not as a substitute for, GAAP financial measures.
- 6The 8-K filing does not contain the specific Q2 2025 financial figures; these are available in the referenced press release.
- 7An interactive data file in XBRL format is also included as part of the filing.